Skip to main content

Table 1 Poliovirus-antibody seropositive subjects according to sex, age, and region (n= 745)

From: A national cross-sectional study for poliovirus seroprevalence in the Republic of Korea in 2012: implication for deficiency in immunity to polio among middle-aged people

  

PV1

PV2

PV3

No. of tested samples (%)

No. of positive samples (%)

P value*

No. of positive samples (%)

P value

No. of positive samples (%)

P value

Total

745

616 (82.7)

 

685 (91.9)

 

509 (68.3)

 

Sex

       

  Male

349 (46.8)

289 (82.8)

0.51

314 (90.0)

0.04

236 (67.6)

0.38

  Female

396 (53.2)

327 (82.6)

 

371 (93.7)

 

273 (68.9)

 

Age (years)

       

  6–10 (IPV)

236 (31.7)

220 (93.2)

<0.01

228 (96.6)

<0.05

207 (87.7)

<0.01

  11–20 (OPV)

216 (29.0)

173 (80.1)

 

199 (92.1)

 

126 (58.3)

 

  21–40 (OPV)

135 (18.1)

106 (78.5)

 

122 (90.4)

 

72 (53.3)

 

  41–60 (OPV)

113 (15.2)

79 (69.9)

 

95 (84.1)

 

74 (65.5)

 

  >60 (OPV)

45 (6.0)

38 (84.4)

 

41 (91.1)

 

30 (66.7)

 

Region

       

  Gyeonggi-do

237 (31.8)

202 (85.2)

0.065

226 (95.4)

0.018

172 (72.6)

0.033

  Gyeongsang-do

170 (22.8)

135 (79.4)

 

154 (90.6)

 

108 (63.5)

 

  Seoul

126 (16.9)

103 (81.7)

 

114 (90.5)

 

80 (63.5)

 

  Chungcheong-do

112 (15.0)

95 (84.8)

 

101 (90.2)

 

85 (75.9)

 

  Jeolla-do

68 (9.1)

54 (79.4)

 

59 (86.8)

 

42 (61.8)

 

  Gangwon-do

24 (3.2)

19 (79.2)

 

23 (95.8)

 

17 (70.8)

 

  Jeju-do

8 (1.1)

8 (100.0)

 

8 (100.0)

 

5 (62.5)

 
  1. *P < 0.05 indicates significant differences of seroprevalence among the compared groups.
  2. IPV, inactivated poliovirus vaccine; OPV, oral poliovirus vaccine; PV, poliovirus.